FTN Equity Downgrades Hi-Tech Pharmacal (HITK) from Buy
HITK Hot Sheet
Rating Summary:2 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
FTN Equity downgrades Hi-Tech Pharmacal (Nasdaq: HITK) to Neutral from Buy.
To see more analyst ratings on HITK Click Here.
Hi-Tech Pharmacal Co., Inc. develops, manufactures, markets, and sells generic, prescription, over-the-counter (OTC), and nutritional products in liquid and semisolid dosage forms in the United States.
To see more analyst ratings on HITK Click Here.
Hi-Tech Pharmacal Co., Inc. develops, manufactures, markets, and sells generic, prescription, over-the-counter (OTC), and nutritional products in liquid and semisolid dosage forms in the United States.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
- UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
